Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls

Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib

(2017) M. J. Fidler et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule

(2017) M. Hidalgo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.

(2017) C. P. Carden et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.

(2017) M. von Mehren et al.   JOURNAL OF CLINICAL ONCOLOGY

Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy.

(2017) R. Karmali et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

(2017) T. Evans et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of AMG 479, a fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF-1R), in Japanese patients (pts) with advanced solid tumors.

(2017) T. Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC).

(2017) S. S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.

(2017) K. Habben et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

(2011) Aung Naing et al.   CLINICAL CANCER RESEARCH

Role of Insulin-Like Growth Factor Binding Protein 2 in Lung Adenocarcinoma

(2010) Toshiro Migita et al.   AMERICAN JOURNAL OF PATHOLOGY

Defining the pathway to insulin-like growth factor system targeting in cancer

(2010) Steven A. Rosenzweig et al.   BIOCHEMICAL PHARMACOLOGY

IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families

(2010) Ann H. Rosendahl et al.   BREAST CANCER RESEARCH AND TREATMENT

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

(2010) A Gualberto et al.   BRITISH JOURNAL OF CANCER

Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

(2010) J. B. Douglas et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

(2010) A. Gualberto et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

(2010) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

(2010) R. Quek et al.   CLINICAL CANCER RESEARCH

The Insulin-Like Growth Factor Pathway in Lung Cancer

(2010) Rafal Dziadziuszko et al.   Journal of Thoracic Oncology

Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation

(2010) H Zhang et al.   ONCOGENE

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients

(2009) V. Ludovini et al.   ANNALS OF ONCOLOGY

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients

(2009) F. Cappuzzo et al.   ANNALS OF ONCOLOGY

The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

(2009) R. T. Kurmasheva et al.   CANCER RESEARCH

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

(2009) C. Desbois-Mouthon et al.   CLINICAL CANCER RESEARCH

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

IGFBP3 polymorphisms and risk of cancer: a meta-analysis

(2009) Li Li et al.   MOLECULAR BIOLOGY REPORTS

Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines

(2009) Z. Duan et al.   MOLECULAR CANCER THERAPEUTICS

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

(2008) E. Buck et al.   CANCER RESEARCH

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

(2008) F. Huang et al.   CANCER RESEARCH

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

(2008) Angelo et al.   Frontiers in Bioscience-Landmark

Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with Increased Mortality

(2008) M. P. Brugts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Role of Endocrine Insulin-Like Growth Factor-I and Insulin in Breast Cancer

(2008) Danielle Lann et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis

(2008) Chang Youl Lee et al.   KOREAN JOURNAL OF INTERNAL MEDICINE